Literature DB >> 20703014

Effects of acarbose on the acceleration of postprandial hyperglycemia-induced pathological changes induced by intermittent hypoxia in lean mice.

Masatoshi Miyamura1, Oliver Schnell, Chika Yamashita, Toshitaka Yoshioka, Chika Matsumoto, Tatsuhiko Mori, Akira Ukimura, Yasushi Kitaura, Yasuo Matsumura, Nobukazu Ishizaka, Tetsuya Hayashi.   

Abstract

Postprandial hyperglycemia (PPH) and intermittent hypoxia related to the sleep apnea syndrome are important predictors of cardiovascular disease. We investigated the effects of intermittent hypoxia on pathological changes in the left ventricular (LV) myocardium caused by PPH in lean mice and evaluated the influence of acarbose, an α-glucosidase inhibitor. Male C57BL/6J mice aged 8 weeks were exposed to intermittent hypoxia (8 h/day during the daytime) or kept under normoxia. PPH was induced by restriction of feeding to 1-h periods twice a day, with the restricted diet (RD) mice receiving either standard chow or chow containing 0.02% acarbose. Another group of mice were fed standard chow ad libitum (AL). Plasma glucose levels after food intake were significantly elevated in RD but not in AL mice, and glucose levels were suppressed by acarbose. Intermittent hypoxia exacerbated cardiomyocyte hypertrophy and interstitial fibrosis in the LV myocardium of RD mice. Superoxide production and expression of 4-hydroxy-2-nonenal in the LV myocardium with intermittent hypoxia were increased in RD mice, but not AL mice. In addition, expression of tumor necrosis factor α (TNF-α) mRNA was increased in hypoxic RD mice. Treatment with acarbose inhibited oxidative stress and TNF-α mRNA expression and preserved the histological architecture of the LV myocardium.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20703014     DOI: 10.1254/jphs.10014fp

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  6 in total

Review 1.  Cardiovascular effects of anti-diabetes drugs.

Authors:  Lisa M Younk; Elizabeth M Lamos; Stephen N Davis
Journal:  Expert Opin Drug Saf       Date:  2016-06-27       Impact factor: 4.250

Review 2.  Widespread sex dimorphism in aging and age-related diseases.

Authors:  Nirmal K Sampathkumar; Juan I Bravo; Yilin Chen; Prakroothi S Danthi; Erin K Donahue; Rochelle W Lai; Ryan Lu; Lewis T Randall; Nika Vinson; Bérénice A Benayoun
Journal:  Hum Genet       Date:  2019-11-01       Impact factor: 4.132

Review 3.  Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes.

Authors:  James J DiNicolantonio; Jaikrit Bhutani; James H O'Keefe
Journal:  Open Heart       Date:  2015-10-19

Review 4.  On the potential of acarbose to reduce cardiovascular disease.

Authors:  Eberhard Standl; Michael J Theodorakis; Michael Erbach; Oliver Schnell; Jaakko Tuomilehto
Journal:  Cardiovasc Diabetol       Date:  2014-04-16       Impact factor: 9.951

5.  Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.

Authors:  David E Harrison; Randy Strong; David B Allison; Bruce N Ames; Clinton M Astle; Hani Atamna; Elizabeth Fernandez; Kevin Flurkey; Martin A Javors; Nancy L Nadon; James F Nelson; Scott Pletcher; James W Simpkins; Daniel Smith; J Erby Wilkinson; Richard A Miller
Journal:  Aging Cell       Date:  2013-11-19       Impact factor: 9.304

6.  Acarbose improves health and lifespan in aging HET3 mice.

Authors:  David E Harrison; Randy Strong; Silvestre Alavez; Clinton Michael Astle; John DiGiovanni; Elizabeth Fernandez; Kevin Flurkey; Michael Garratt; Jonathan A L Gelfond; Martin A Javors; Moshe Levi; Gordon J Lithgow; Francesca Macchiarini; James F Nelson; Stacey J Sukoff Rizzo; Thomas J Slaga; Tim Stearns; John Erby Wilkinson; Richard A Miller
Journal:  Aging Cell       Date:  2019-01-27       Impact factor: 9.304

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.